Klebsiella infectious disease

Summary

Klebsiella infectious disease (MONDO:0030603) is a disease and 5 clinical trials. Top therapeutic interventions include ertapenem, piperacillin, and sitafloxacin anhydrous. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Klebsiella infectious disease
Mondo ID	MONDO:0030603
MeSH	D007710
SNOMED CT	721756002
Is cancer (heuristic)	no

Also known as: infection, Klebsiella · infections, Klebsiella · Klebsiella caused disease or disorder · Klebsiella disease or disorder · Klebsiella infection

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › Klebsiella infectious disease

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (3): granuloma inguinale, rhinoscleroma, Klebsiella pneumonia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02729116	PHASE2/PHASE3	UNKNOWN	Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
NCT00167986	Not specified	COMPLETED	Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
NCT00167999	Not specified	COMPLETED	Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
NCT00363220	Not specified	COMPLETED	Community - Associated Extended-spectrum Beta-lactamases (ESBL)
NCT05193045	Not specified	UNKNOWN	Prognosis of Klebsiella ESBL Sepsis: Role of 2-HYDRoxy-myristate in Endotoxin Structure

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ERTAPENEM	4	1
PIPERACILLIN	4	1
SITAFLOXACIN ANHYDROUS	3	2